Alzheimer’s disease is most commonly described in three broad stages: early (mild), middle (moderate), and late (severe). However, some clinical frameworks break the disease into as many as seven stages, and the latest research guidelines treat it as a continuous spectrum rather than a set of distinct steps. The answer depends on which staging system you’re looking at and why it’s being used.
The 3-Stage Model Most People Encounter
The framework used by the Alzheimer’s Association and most major health organizations divides the disease into three clinical stages based on how much a person’s daily life is affected: mild, moderate, and severe. This is the model your doctor will most likely use when explaining a diagnosis to you or your family.
On average, a person with Alzheimer’s lives between 3 and 11 years after diagnosis, though some live 20 years or more. The middle stage is typically the longest, often lasting for many years, while the early and late stages tend to be shorter. Progression varies enormously from person to person, so these timelines are rough guides rather than fixed windows.
What Each Stage Looks Like
Early (Mild) Stage
In the early stage, a person can still function independently for the most part. They may drive, work, and handle their own finances, but they start noticing memory lapses that go beyond normal aging. Forgetting recent conversations, misplacing things, and struggling to find the right word in conversation are common. Friends and family often notice these changes before the person does. This stage can last for a few years before symptoms become more disruptive.
Middle (Moderate) Stage
The middle stage is where most of the caregiving demands emerge. A person in this stage begins losing the ability to manage everyday tasks they once handled without thinking: paying bills, choosing appropriate clothing, cooking meals, or keeping track of appointments. Confusion about time and place becomes more frequent, and personality changes often surface. Some people become withdrawn or suspicious; others grow agitated or restless. Wandering is a real safety concern during this stage. Because it lasts the longest, this is the period when families typically need to arrange consistent daily support or look into assisted living.
Late (Severe) Stage
In the late stage, the disease affects the body as much as the mind. A person loses the ability to carry on a conversation, control movement, and eventually swallow safely. Difficulty chewing and swallowing raises the risk of choking and aspiration pneumonia, which is one of the most common causes of death in people with advanced Alzheimer’s. Some people develop sudden muscle jerks or spasms in the arms, legs, or whole body, which can look like seizures but don’t involve loss of consciousness. Prolonged immobility leads to pressure sores and skin breakdown. At this point, a person needs around-the-clock care for all basic needs.
The 7-Stage Scale
Some clinicians use a more granular system called the Global Deterioration Scale (also known as the Reisberg scale), which breaks Alzheimer’s into seven stages. Stages 1 through 3 cover the range from no impairment to mild cognitive decline. Stages 4 and 5 map roughly onto what the 3-stage model calls moderate Alzheimer’s. Stages 6 and 7 describe increasingly severe decline, including loss of speech and the ability to walk.
This 7-stage framework is useful because the jump between “mild” and “moderate” in the 3-stage model is enormous. Breaking it into finer steps helps caregivers and clinicians track smaller changes and plan ahead more precisely. You may encounter it in support group materials, caregiving guides, or detailed care plans.
Where Mild Cognitive Impairment Fits In
Before Alzheimer’s symptoms become obvious enough to qualify as even the early stage, many people pass through a phase called mild cognitive impairment, or MCI. People with MCI notice memory problems that are worse than typical aging but can still take care of themselves and carry out their normal daily activities. MCI doesn’t always lead to Alzheimer’s. Some people with MCI stay stable, and a small percentage actually improve. But for those who do progress, MCI often represents the transitional zone between a healthy brain and early-stage Alzheimer’s.
The Biological View: A Continuous Spectrum
In 2024, the National Institute on Aging and the Alzheimer’s Association published revised diagnostic criteria that reframe Alzheimer’s as a biological continuum rather than a series of discrete stages. Under this framework, Alzheimer’s is defined by measurable brain changes (detected through blood tests and brain scans) that begin years or even decades before any symptoms appear. The disease then progresses through increasing levels of those biological changes, eventually producing the cognitive decline people associate with the diagnosis.
This matters because brain changes tied to Alzheimer’s can now be detected through newer blood-based biomarkers, making earlier identification possible. For now, though, these biological staging tools are intended for evaluating people who already have symptoms, not for screening healthy individuals. The revised criteria specifically note that testing asymptomatic people for Alzheimer’s-related brain changes is not recommended outside of research settings, partly because no treatments have been approved for people without symptoms.
Which Staging System Should You Pay Attention To?
If you’re a caregiver or family member trying to understand where someone falls in the disease, the 3-stage model gives you the clearest big picture. It tells you what to expect in practical terms: how much help the person needs now, what’s likely coming next, and roughly how much time you’re working with. The 7-stage scale is helpful when you want more detail, especially for tracking gradual changes in the moderate phase or communicating specific concerns to a care team.
The biological staging framework is less relevant to day-to-day caregiving but increasingly important for understanding diagnosis. As blood-based tests become more widely available, you may hear your doctor reference biological markers alongside the traditional clinical stages. These two perspectives aren’t competing. They describe the same disease from different angles: one focused on what a person can do, the other on what’s happening in the brain.